GrunbergS., DeusonR., MavrosP.: Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.Cancer, 100: 2261, 2004.
2.
DeVaneC.L., SubstanceP.: A new era, a new role.Pharmacotherapy, 21: 1061–1069, 2001.
3.
HeskethP.J.: Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting.Support Care Cancer, 9: 350–354, 2001.
4.
CocquytV., Van BelleS., ReinhardtR.R.: Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-in-duced emesis.Eur J Cancer, 37: 835–842, 2001.
5.
CamposD., PereiraJ.R., ReinhardtR.R.: Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.J Clin Oncol, 19: 1759–1767, 2001.
6.
NavariR., ReinhardtR., GrallaR.J.: Reduction of cisplatin-induced emesis by a selective neu-rokinin-1 receptor antagonist.N Engl J Med, 340: 190–195, 1999.
7.
HeskethP.J., GrunbergS.M., GrallaR.J.: The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting; a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. The Aprepitant Protocol 052 Study Group.J Clin Oncol, 21: 4112–4119, 2003.
8.
Poli-BigelliS., Rodrigues PereiraJ., CaridesA.D.: Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of CINV.Cancer, 97: 3090–3098, 2003.
9.
AaproM.S., SchmollH.J., Poli-BigelliS.: Comparison of aprepitant combination regimen with 4-day ondansetron + 4-day dexamethasone for prevention of acute and delayed nausea-vomiting after cisplatin chemotherapy.Oral presentation, ASCO 2005 (N 8007).
10.
DeWitR., HerrstedtJ., RapoportB.: The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.Eur J Cancer, 40: 403–410, 2004.
11.
The Italian Group for Antiemetic Research: Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy.N Engl J Med, 342: 1554–1559, 2000.
12.
The Italian Group for Antiemetic Research: Delayed emesis induced by moderately emetoge-nic chemotherapy. Do we need to treat all patients?Ann Oncol, 8: 561–567, 1997.
13.
WarrD.G., HeskethP.J., GrallaR.J.: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after MEC.J Clin Oncol, 22: 2822–2830, 2005.
14.
MartinA.R., PearsonJ.D., CaiB.: Validation of a 5-day recall version of the Functional Living Index-Emesis (FLIE) quality of life questionnaire for chemotherapy-induced emesis.Qual Life Res, 9: 18, 2000.
15.
LoftersW.S., PaterJ.L., ZeeB.: Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to MEC.J Clin Oncol, 15: 2966–2973, 1997.
16.
SigsgaardT.C., HerrstedtJ., AndersenL.J.: Granisetron compared with prednisolone plus metopimazine as antiemetic prophylaxis during multiple cycles of MEC.Br J Cancer, 80: 412–418, 1999.
17.
SigsgaardT.C., HerrstedtJ., HandbergJ.: Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis during multiple cycles of MEC.J Clin Oncol, 19: 2091–2097, 2001.
18.
HerrstedtJ., MussH.B., WarrD.G.: Efficacy and tolerability of aprepitant for the prevention of CINV over multiple cycles of MEC.Cancer, 104: 1548–1555, 2005.
19.
BeckT.M.: The pattern of emesis following high-dose cyclophosphamide and the antiemetic efficacy of ondansetron.Anti-Cancer Drugs, 6: 237–242, 1995.
20.
Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC).Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference.Ann Oncol, 9: 811, 1998.
RoilaF., BoschettiE., TonatoM.: Predictive factors of delayed emesis in cisplatin treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study.Am J Clin Oncol, 14: 238–242, 1991.
23.
AaproM.: Optimising antiemetic therapy: what are problems and how can they be overcome?Curr Med Res Opin, 21, 6: 885–897, 2005.
